Unexpected acute pulmonary embolism in an old COVID-19 patient with warfarin overdose: a case report.

COVID-19 Case report D-dimer Overdose Pulmonary embolism Warfarin

Journal

European heart journal. Case reports
ISSN: 2514-2119
Titre abrégé: Eur Heart J Case Rep
Pays: England
ID NLM: 101730741

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 04 01 2021
revised: 02 02 2021
accepted: 12 05 2021
entrez: 9 6 2021
pubmed: 10 6 2021
medline: 10 6 2021
Statut: epublish

Résumé

Severe acute respiratory syndrome coronavirus 2 disease is strongly associated with a high incidence of thrombotic events. Anticoagulation could be a cornerstone in successfully managing severe forms of coronavirus disease 2019 (COVID-19). However, optimal anticoagulant dosing in elderly patients is challenging because of high risk of both thrombosis and bleeding. We present here the case of an 89-year-old patient receiving warfarin for atrial fibrillation and valvular heart disease, admitted to the intensive care unit for respiratory failure due to COVID-19. The patient presented with a severe epistaxis associated with warfarin overdose [international normalized ratio (INR) > 10]. After a successful initial reversal using vitamin K This case report illustrates the complexity of COVID-19 pathophysiology and its management for physicians, especially in patients receiving vitamin K antagonists (VKAs). Infection, concurrent medication use, and pharmacogenetic factors involved in VKA metabolism and pharmacodynamics may lead to a loss of control of anticoagulation. Pulmonary embolism should still be considered in COVID-19 patients even with effective or overdosed anticoagulant therapy.

Sections du résumé

BACKGROUND BACKGROUND
Severe acute respiratory syndrome coronavirus 2 disease is strongly associated with a high incidence of thrombotic events. Anticoagulation could be a cornerstone in successfully managing severe forms of coronavirus disease 2019 (COVID-19). However, optimal anticoagulant dosing in elderly patients is challenging because of high risk of both thrombosis and bleeding.
CASE SUMMARY METHODS
We present here the case of an 89-year-old patient receiving warfarin for atrial fibrillation and valvular heart disease, admitted to the intensive care unit for respiratory failure due to COVID-19. The patient presented with a severe epistaxis associated with warfarin overdose [international normalized ratio (INR) > 10]. After a successful initial reversal using vitamin K
DISCUSSION CONCLUSIONS
This case report illustrates the complexity of COVID-19 pathophysiology and its management for physicians, especially in patients receiving vitamin K antagonists (VKAs). Infection, concurrent medication use, and pharmacogenetic factors involved in VKA metabolism and pharmacodynamics may lead to a loss of control of anticoagulation. Pulmonary embolism should still be considered in COVID-19 patients even with effective or overdosed anticoagulant therapy.

Identifiants

pubmed: 34104863
doi: 10.1093/ehjcr/ytab206
pii: ytab206
pmc: PMC8178933
doi:

Types de publication

Case Reports

Langues

eng

Pagination

ytab206

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

Références

Arch Intern Med. 2005 May 23;165(10):1095-106
pubmed: 15911722
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
J Thromb Thrombolysis. 2020 Nov;50(4):814-821
pubmed: 32748122
SN Compr Clin Med. 2020 Aug 19;:1-3
pubmed: 32839751
J Am Coll Cardiol. 2020 Jul 28;76(4):480-482
pubmed: 32479784
Crit Care. 2020 Nov 23;24(1):653
pubmed: 33225952
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
JAMA. 2002 Apr 3;287(13):1690-8
pubmed: 11926893
Int J Cardiol. 2021 Apr 15;329:266-269
pubmed: 33309764
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973
pubmed: 32311448
Lancet Haematol. 2020 Jun;7(6):e438-e440
pubmed: 32407672
Intensive Care Med. 2020 Aug;46(8):1603-1606
pubmed: 32415314
Chest. 2012 Feb;141(2 Suppl):e152S-e184S
pubmed: 22315259

Auteurs

Maxime Coutrot (M)

Department of Anaesthesiology, Critical Care Medicine and Burn Unit, AP-HP, Saint Louis and Lariboisière University Hospitals, 1 Avenue Claude Vellefaux, 75010 Paris, France.
INSERM UMR-S 942, 41 boulevard de la Chapelle, 75475 Paris Cedex 10, Lariboisière Hospital, Paris, France.
FHU PROMICE, 2 Rue Ambroise Paré, 75010 Paris‌, France.

Maxime Delrue (M)

Service d'hématologie biologique, Hôpital Lariboisière, 2rue Ambroise Pare ´,75010 Paris, Université de Paris, Paris, France.
EA 3518, Institut de Recherche Saint-Louis, 1 Avenue Claude Vellefaux, 75010 Paris, Université de Paris, Paris, France.

Bérangère S Joly (BS)

Service d'hématologie biologique, Hôpital Lariboisière, 2rue Ambroise Pare ´,75010 Paris, Université de Paris, Paris, France.
EA 3518, Institut de Recherche Saint-Louis, 1 Avenue Claude Vellefaux, 75010 Paris, Université de Paris, Paris, France.

Virginie Siguret (V)

Service d'hématologie biologique, Hôpital Lariboisière, 2rue Ambroise Pare ´,75010 Paris, Université de Paris, Paris, France.
INSERM UMR-S 1140 Innovations thérapeutiques en Hémostase, Faculté de Pharmacie, 4 avenue de l'Observatoire, 75270 Paris CEDEX 06, Université de Paris, Paris, France.

Classifications MeSH